- Home
- OMER vs CYRX Comparison
OMER vs CYRX Comparison
Compare OMER & CYRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OMER
- CYRX
- Stock Information
- Founded
- OMER 1994
- CYRX 1999
- Country
- OMER United States
- CYRX United States
- Employees
- OMER N/A
- CYRX N/A
- Industry
- OMER Biotechnology: Pharmaceutical Preparations
- CYRX Biotechnology: Pharmaceutical Preparations
- Sector
- OMER Health Care
- CYRX Health Care
- Exchange
- OMER Nasdaq
- CYRX Nasdaq
- Market Cap
- OMER 513.8M
- CYRX 438.7M
- IPO Year
- OMER 2009
- CYRX N/A
- Fundamental
- Price
- OMER $8.83
- CYRX $8.52
- Analyst Decision
- OMER Strong Buy
- CYRX Strong Buy
- Analyst Count
- OMER 5
- CYRX 9
- Target Price
- OMER $27.50
- CYRX $12.83
- AVG Volume (30 Days)
- OMER 1.7M
- CYRX 696.4K
- Earning Date
- OMER 11-13-2025
- CYRX 11-04-2025
- Dividend Yield
- OMER N/A
- CYRX N/A
- EPS Growth
- OMER N/A
- CYRX N/A
- EPS
- OMER N/A
- CYRX 1.27
- Revenue
- OMER N/A
- CYRX $243,795,000.00
- Revenue This Year
- OMER N/A
- CYRX N/A
- Revenue Next Year
- OMER N/A
- CYRX $9.20
- P/E Ratio
- OMER N/A
- CYRX $6.73
- Revenue Growth
- OMER N/A
- CYRX 41.27
- 52 Week Low
- OMER $2.95
- CYRX $4.58
- 52 Week High
- OMER $13.60
- CYRX $11.44
- Technical
- Relative Strength Index (RSI)
- OMER 67.40
- CYRX 41.79
- Support Level
- OMER $6.24
- CYRX $8.14
- Resistance Level
- OMER $7.06
- CYRX $9.29
- Average True Range (ATR)
- OMER 0.54
- CYRX 0.53
- MACD
- OMER 0.02
- CYRX -0.06
- Stochastic Oscillator
- OMER 99.65
- CYRX 24.52
About OMER Omeros Corporation
Omeros Corp is a United States-based clinical-stage biopharmaceutical company engaged in discovering, developing, and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting immunologic disorders including complement-mediated diseases, cancers, and addictive and compulsive disorders. The drug candidate in the pipeline of complement-targeted therapeutics is narsoplimab (OMS721), a proprietary, patented human monoclonal antibody targeting mannan-binding lectin-associated serine protease 2, the key activator of the lectin pathway of complement. Clinical development of narsoplimab is currently focused on hematopoietic stem cell transplant-associated thrombotic microangiopathy and immunoglobulin nephropathy.
About CYRX CryoPort Inc.
CryoPort Inc is a leader serving the life sciences industry as a provider of integrated temperature-controlled supply chain solutions supporting the life sciences in the biopharma/pharma, animal health, and reproductive medicine markets. It operates in two reportable segments: Life Sciences Services and Life Sciences Products. Geographically the company operates in the Americas, Europe, the Middle East and Africa (EMEA), and Asia Pacific (APAC), generating a majority of its revenue from the Americas.